Removing the primary tumour in metastatic breast cancer
Mené sur 350 patientes atteintes d'un cancer du sein métastatique "de novo" (âge : inférieur ou égal à 65 ans ; durée médiane de suivi : 23 mois), cet essai évalue, du point de vue de la survie globale à 2 ans, l'intérêt d'un traitement locorégional
During the past 100 years, the underpinning philosophy of the treatment of breast cancer has changed from exclusive local therapy, to a disease conceived as likely to be systemic from the start, so that most patients presenting with potentially curable disease have both local (surgical, radiotherapeutic, or both) and systemic therapy. In many centres, the proportion of patients with metastatic disease at first presentation is less than 10%, and these patients are primarily given systemic therapy.
The Lancet Oncology , commentaire, 2014